Statement of Principles concerning malignant neoplasm of the salivary gland (Reasonable Hypothesis) (No. 102 of 2023)

Administered by Department of Veterans' Affairs

Legislation au F2023L01430 In force Legislative Instrument

Legislation content

EXPLANATORY STATEMENT

 

STATEMENT OF PRINCIPLES CONCERNING

MALIGNANT NEOPLASM OF THE SALIVARY GLAND

(REASONABLE HYPOTHESIS) (No. 102 of 2023)

 

VETERANS' ENTITLEMENTS ACT 1986

MILITARY REHABILITATION AND COMPENSATION ACT 2004

 

  1. This is the Explanatory Statement to the Statement of Principles concerning malignant neoplasm of the salivary gland (Reasonable Hypothesis) (No. 102 of 2023).

Background

2.             The Repatriation Medical Authority (the Authority), under subsection 196B(8) of the Veterans' Entitlements Act 1986 (the VEA), repeals Instrument No. 57 of 2015 (Federal Register of Legislation No. F2015L00252) determined under subsections 196B(2) and (8) of the VEA concerning malignant neoplasm of the salivary gland.

3.             The Authority is of the view that there is sound medical-scientific evidence that indicates that malignant neoplasm of the salivary gland and death from malignant neoplasm of the salivary gland can be related to particular kinds of service.  The Authority has therefore determined pursuant to subsection 196B(2) of the VEA a Statement of Principles concerning malignant neoplasm of the salivary gland (Reasonable Hypothesis) (No. 102 of 2023).  This Instrument will in effect replace the repealed Statement of Principles.

Purpose and Operation

4.             The Statement of Principles will be applied in determining claims under the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).

5.             The Statement of Principles sets out the factors that must as a minimum exist, and which of those factors must be related to the following kinds of service rendered by a person:

 operational service under the VEA;

 peacekeeping service under the VEA;

 hazardous service under the VEA;

 British nuclear test defence service under the VEA;

 warlike service under the MRCA;

 non-warlike service under the MRCA,

before it can be said that a reasonable hypothesis has been raised connecting malignant neoplasm of the salivary gland or death from malignant neoplasm of the salivary gland, with the circumstances of that service.  The Statement of Principles has been determined for the purposes of both the VEA and the MRCA.

6.             This Instrument results from an investigation notified by the Authority in the Government Notices Gazette of 10 May 2022 concerning malignant neoplasm of the salivary gland in accordance with section 196G of the VEA.  The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

7.             The contents of this Instrument are in similar terms as the repealed Instrument.  Comparing this Instrument and the repealed Instrument, the differences include:

  • adopting the latest revised Instrument format, which commenced in 2015;
  • specifying a day of commencement for the Instrument in section 2;
  • revising the definition of 'malignant neoplasm of the salivary gland' in subsection 7(2);
  • revising the factors in Section 9 that must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting malignant neoplasm of the salivary gland or death from malignant neoplasm of the salivary gland with the circumstances of a veteran's relevant service. The revision is required to reflect advances in sound medical scientific evidence that have occurred since the repealed Statement of Principles was made;
  • new factor in subsection 9(5) concerning having smoked tobacco products;
  • deleting factor concerning being exposed to mustard gas at least five years before the clinical onset of malignant neoplasm of the salivary gland; and
  • new definitions of 'MRCA', 'one pack-year' and 'VEA' in Schedule 1  Dictionary.

Incorporation

8.             The definition of "cumulative equivalent dose" contained in the Schedule 1 – Dictionary incorporates the Guide to calculation of 'cumulative equivalent dose' for the purpose of applying ionising radiation factors contained in Statements of Principles determined under Part XIA of the Veterans' Entitlements Act 1986 (Cth), Australian Radiation Protection and Nuclear Safety Agency, as in force on 2 August 2017.  This writing is incorporated pursuant to subsection 14(b) of the Legislation Act 2003.

9.             A copy of this document is available to any person on the website of the Repatriation Medical Authority at www.rma.gov.au or from the Repatriation Medical Authority, Level 8, 480 Queen St, Brisbane, Queensland 4000, by contacting the Registrar on telephone (07) 3815 9404.

Consultation

10.         Prior to determining this Instrument, the Authority advertised its intention to undertake an investigation in relation to malignant neoplasm of the salivary gland in the Government Notices Gazette of 10 May 2022, and circulated a copy of the notice of intention to investigate to a wide range of organisations representing veterans, service personnel and their dependants.  The Authority invited submissions from the Repatriation Commission, the Military Rehabilitation and Compensation Commission, organisations and persons referred to in section 196E of the VEA, and any person having expertise in the field.  No submissions were received for consideration by the Authority in relation to the investigation.

11.         On 10 July 2023, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instrument and the medical-scientific material considered by the Authority.  This letter emphasised the deletion of factors relating to 'being exposed to mustard gas at least five years before the clinical onset of malignant neoplasm of the salivary gland'.  The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instrument prior to its determination.  No submissions were received for consideration by the Authority.  No changes were made to the proposed Instrument following this consultation process.

Human Rights

12.         This instrument is compatible with the Human Rights and Freedoms recognised or declared in the International Instruments listed in Section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.  A Statement of Compatibility with Human Rights follows.

Finalisation of Investigation

13.         The determining of this Instrument finalises the investigation in relation to malignant neoplasm of the salivary gland as advertised in the Government Notices Gazette of 10 May 2022.

References

14.         A list of references relating to the above condition is available on the Authority's website at: www.rma.gov.au. Any other document referred to in this Statement of Principles is available on request to the Repatriation Medical Authority at the following address:

              

Email:    info@rma.gov.au

Post:      The Registrar

Repatriation Medical Authority

GPO Box 1014

BRISBANE    QLD    4001

 


Statement of Compatibility with Human Rights

(Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011)

 

Instrument No.:   Statement of Principles No. 102 of 2023

Kind of Injury, Disease or Death: Malignant neoplasm of the salivary gland

 

This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

Overview of the Legislative Instrument

1. This Legislative Instrument is determined pursuant to subsection 196B(2) of the Veterans' Entitlements Act 1986 (the VEA) for the purposes of the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).  Part XIA of the VEA requires the determination of these instruments outlining the factors connecting particular kinds of injury, disease or death with service such being determined solely on the available sound medical-scientific evidence.

2. This Legislative Instrument:-

  • facilitates claimants in making, and the Repatriation Commission and the Military Rehabilitation and Compensation Commission in assessing, claims under the VEA and the MRCA respectively, by specifying the circumstances in which medical treatment and compensation can be extended to eligible persons who have malignant neoplasm of the salivary gland;
  • facilitates the review of such decisions by the Veterans' Review Board and the Administrative Appeals Tribunal;
  • outlines the factors which the current sound medical-scientific evidence indicates must as a minimum exist, before it can be said that a reasonable hypothesis has been raised, connecting malignant neoplasm of the salivary gland with the circumstances of eligible service rendered by a person, as set out in clause 5 of the Explanatory Statement;
  • replaces Instrument No. 57 of 2015; and
  • reflects developments in the available sound medical-scientific evidence concerning malignant neoplasm of the salivary gland which have occurred since that earlier instrument was determined. 

3. The Instrument is assessed as being a technical instrument which improves the medico-scientific quality of outcomes under the VEA and the MRCA. 

Human Rights Implications

4. This Legislative Instrument does not derogate from any human rights. It promotes the human rights of veterans, current and former Defence Force members as well as other persons such as their dependents, including:

  • the right to social security (Art 9, International Covenant on Economic, Social and Cultural Rights; Art 26, Convention on the Rights of the Child and Art 28, Convention on the Rights of Persons with Disabilities) by helping to ensure that the qualifying conditions for the benefit are 'reasonable, proportionate and transparent'[1];
  • the right to an adequate standard of living (Art 11, ICESCR; Art 27, CRC and Art 28, CRPD) by facilitating the assessment and determination of social security benefits;
  • the right to the enjoyment of the highest attainable standard of physical and mental health (Art 12, ICESCR and Art 25, CRPD), by facilitating the assessment and determination of compensation and benefits in relation to the treatment and rehabilitation of veterans and Defence Force members;
  • the rights of persons with disabilities by facilitating the determination of claims relating to treatment and rehabilitation (Art 26, CRPD); and
  • ensuring that those rights "will be exercised without discrimination of any kind as to race, colour, sex, language, religion, political or other opinion, national or social origin, property, birth or other status" (Art 2, ICESCR).

Conclusion

This Legislative Instrument is compatible with human rights as it does not derogate from and promotes a number of human rights.

 

Repatriation Medical Authority

 

 

 

 

 

 

[1] In General Comment No. 19 (The right to social security), the Committee on Economic, Social and Cultural Rights said (at paragraph 24) this to be one of the elements of ensuring accessibility to social security.

Overview

The Statement of Principles concerning malignant neoplasm of the salivary gland (Reasonable Hypothesis) (No. 102 of 2023) was enacted to address the gap in addressing claims related to malignant neoplasm of the salivary gland among veterans, as identified by the Repatriation Medical Authority (the Authority). This instrument was determined under subsection 196B(2) of the Veterans' Entitlements Act 1986 (VEA) and applies to claims under both the VEA and the Military Rehabilitation and Compensation Act 2004 (MRCA). The Statement of Principles outlines the minimum factors that must exist to establish a reasonable hypothesis connecting malignant neoplasm of the salivary gland with certain types of service. This instrument replaces Instrument No. 57 of 2015, reflecting the latest sound medical-scientific evidence. The Authority's decision to determine this instrument follows an investigation into the condition, announced in the Government Notices Gazette on 10 May 2022, and consultation with relevant organisations and experts. The instrument is compatible with human rights and aims to facilitate the assessment and determination of benefits for veterans and their dependents, ensuring these benefits are reasonable, proportionate, and transparent.

Scope and Application

The Statement of Principles concerning malignant neoplasm of the salivary gland (Reasonable Hypothesis) (No. 102 of 2023) applies to veterans and their dependants who are eligible for benefits under the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. It establishes the circumstances in which a reasonable hypothesis may be raised that malignant neoplasm of the salivary gland, or death from such a neoplasm, is connected with particular kinds of service rendered by a person, including operational, peacekeeping, hazardous, British nuclear test defence service, warlike, and non-warlike service. The Statement of Principles is determined under the authority of the Veterans' Entitlements Act 1986 and applies both nationally and federally, influencing the assessment of claims for medical treatment and compensation by the Repatriation Commission and the Military Rehabilitation and Compensation Commission respectively. The Instrument does not specify any exclusions, exemptions, or thresholds, and while it does not extend or restrict application through subordinate instruments, it does incorporate the Guide to calculation of 'cumulative equivalent dose' for applying ionising radiation factors. The Authority has ensured that the Statement of Principles is compatible with human rights, promoting the rights of veterans, current and former Defence Force members, and their dependents, including social security, an adequate standard of living, and the highest attainable standard of physical and mental health.

Key Provisions

The main operative sections of this legislation (Section 2) outline the repeal of Instrument No. 57 of 2015 and the determination of a new Statement of Principles concerning malignant neoplasm of the salivary gland (Reasonable Hypothesis) (No. 102 of 2023). This Statement of Principles, set out in Section 9, identifies the factors that must exist, and which of those factors must be related to specific types of service, before it can be said that a reasonable hypothesis has been raised connecting malignant neoplasm of the salivary gland or death from malignant neoplasm of the salivary gland with the circumstances of that service. The legislation also incorporates the latest format for Statements of Principles and updates definitions to reflect advances in medical-scientific evidence. The new Statement of Principles will apply to claims under the Veterans' Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA). The obligations imposed by this legislation include the requirement for claimants to provide evidence that meets the factors outlined in the Statement of Principles to establish a connection between their malignant neoplasm of the salivary gland and their service. The Repatriation Medical Authority (the Authority) is responsible for determining these Statements of Principles based on sound medical-scientific evidence and ensuring they are applied in assessing claims. The legislation also mandates the incorporation of the latest Guide to calculation of 'cumulative equivalent dose' for the purpose of applying ionising radiation factors. The legislation outlines civil and criminal consequences for breaches, although specific offences and penalties are not detailed in the provided text. Generally, breaches of legislative requirements under the VEA and MRCA may result in penalties as prescribed by the respective Acts. The Authority is responsible for enforcing compliance with these legislative requirements. Overall, the Statement of Principles serves to clarify the connection between malignant neoplasm of the salivary gland and service for the purposes of claims under the VEA and MRCA, promoting the human rights of veterans and service personnel by facilitating the assessment and determination of benefits and compensation.

Legal classification tags

Area of Law
Veterans' Affairs
Instrument
Regulation
Concepts
Definitions & Interpretation
Reporting & Disclosure Obligations
Compliance Obligations
Consultation Requirements
Catchwords
Statement of Principles

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.